107 related articles for article (PubMed ID: 25579121)
1. The anaplastic lymphoma kinase testing conundrum.
Conde E; Taniere P; Lopez-Rios F
Expert Rev Mol Diagn; 2015 Feb; 15(2):161-3. PubMed ID: 25579121
[TBL] [Abstract][Full Text] [Related]
2. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
[TBL] [Abstract][Full Text] [Related]
3. Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing.
V Laffert M; Warth A; Penzel R; Schirmacher P; Jonigk D; Kreipe H; Schildhaus HU; Merkelbach-Bruse S; Büttner R; Reu S; Kerler R; Jung A; Kirchner T; Wölfel C; Petersen I; Rodriguez R; Jochum W; Bartsch H; Fisseler-Eckhoff A; Berg E; Lenze D; Dietel M; Hummel M
Lung Cancer; 2013 Aug; 81(2):200-6. PubMed ID: 23669200
[TBL] [Abstract][Full Text] [Related]
4. Improving Selection Criteria for ALK Inhibitor Therapy in Non-Small Cell Lung Cancer: A Pooled-Data Analysis on Diagnostic Operating Characteristics of Immunohistochemistry.
Jiang L; Yang H; He P; Liang W; Zhang J; Li J; Liu Y; He J
Am J Surg Pathol; 2016 May; 40(5):697-703. PubMed ID: 26825369
[TBL] [Abstract][Full Text] [Related]
5. Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria.
von Laffert M; Warth A; Penzel R; Schirmacher P; Kerr KM; Elmberger G; Schildhaus HU; Büttner R; Lopez-Rios F; Reu S; Kirchner T; Pauwels P; Specht K; Drecoll E; Höfler H; Aust D; Baretton G; Bubendorf L; Stallmann S; Fisseler-Eckhoff A; Soltermann A; Tischler V; Moch H; Penault-Llorca F; Hager H; Schäper F; Lenze D; Hummel M; Dietel M
J Thorac Oncol; 2014 Nov; 9(11):1685-92. PubMed ID: 25436802
[TBL] [Abstract][Full Text] [Related]
6. Multicenter ALK testing in non-small-cell lung cancer: results of a round robin test.
von Laffert M; Penzel R; Schirmacher P; Warth A; Lenze D; Hummel M; Dietel M
J Thorac Oncol; 2014 Oct; 9(10):1464-9. PubMed ID: 25170635
[TBL] [Abstract][Full Text] [Related]
7. Targeting anaplastic lymphoma kinase in lung cancer.
Shaw AT; Solomon B
Clin Cancer Res; 2011 Apr; 17(8):2081-6. PubMed ID: 21288922
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review).
Di Maio M; De Marinis F; Hirsch FR; Gridelli C
Int J Oncol; 2014 Aug; 45(2):509-15. PubMed ID: 24859689
[TBL] [Abstract][Full Text] [Related]
9. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing.
Wallander ML; Geiersbach KB; Tripp SR; Layfield LJ
Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552
[TBL] [Abstract][Full Text] [Related]
10. Profile of Ventana ALK (D5F3) companion diagnostic assay for non-small-cell lung carcinomas.
Conde E; Hernandez S; Prieto M; Martinez R; Lopez-Rios F
Expert Rev Mol Diagn; 2016 Jun; 16(6):707-13. PubMed ID: 27031368
[TBL] [Abstract][Full Text] [Related]
11. Experience in integrating ALK testing and crizotinib into the routine treatment of patients with non-small cell lung cancer.
Gautschi O; Schefer H; Riklin C; Strobel K; Diebold J
Onkologie; 2013; 36(6):342-7. PubMed ID: 23774148
[TBL] [Abstract][Full Text] [Related]
12. Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer.
Solomon B; Wilner KD; Shaw AT
Clin Pharmacol Ther; 2014 Jan; 95(1):15-23. PubMed ID: 24091716
[TBL] [Abstract][Full Text] [Related]
13. [Diagnosis for ALK positive non-small cell lung cancer].
Feng Q; Yang X; Lin D
Zhongguo Fei Ai Za Zhi; 2015 Feb; 18(2):61-8. PubMed ID: 25676397
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of the anaplastic lymphoma kinase.
Mologni L
Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
[TBL] [Abstract][Full Text] [Related]
15. Journey of the ALK-inhibitor CH5424802 to phase II clinical trial.
Latif M; Saeed A; Kim SH
Arch Pharm Res; 2013 Sep; 36(9):1051-4. PubMed ID: 23700294
[TBL] [Abstract][Full Text] [Related]
16. The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer.
D'Arcangelo M; Wynes MW; Hirsch FR
Curr Opin Oncol; 2013 Mar; 25(2):121-9. PubMed ID: 23385859
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy for NSCLC: ALK inhibition.
Pearson R; Kolesar JM
J Oncol Pharm Pract; 2012 Jun; 18(2):271-4. PubMed ID: 21844131
[TBL] [Abstract][Full Text] [Related]
18. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.
Malik SM; Maher VE; Bijwaard KE; Becker RL; Zhang L; Tang SW; Song P; Liu Q; Marathe A; Gehrke B; Helms W; Hanner D; Justice R; Pazdur R
Clin Cancer Res; 2014 Apr; 20(8):2029-34. PubMed ID: 24573551
[TBL] [Abstract][Full Text] [Related]
19. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
O'Bryant CL; Wenger SD; Kim M; Thompson LA
Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
[TBL] [Abstract][Full Text] [Related]
20. Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives.
Lee JA; Bubendorf L; Stahel R; Peters S
Expert Rev Anticancer Ther; 2013 May; 13(5):625-36. PubMed ID: 23617353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]